Clinical Trials Logo
  1. Home
  2. Opioid-induced Constipation
  3. NCT03638440

Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. — NACASY  

Opioid Induced Constipation Clinical Trial

Official title:
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With Opioid Induced Constipation.

Clinical Trial Summary

This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical practice. Subjects who are receiving Naloxegol (prescribed by their physician according to the SmPC, which recommends that all currently used maintenance laxative therapy should be halted) during the enrolment period may be eligible for enrolment into the study.

Clinical Trial Description

The objective of this study is to assess the safety and efficacy of Naloxegol in a real world setting in cancer patients. The primary safety end point is the incidence of adverse events leading to study discontinuation. The primary efficacy end point is the response rate assessed in the 4 week observation period. Response is defined as three or more bowel movements (without the use of rescue laxative treatment in the previous 24 hours) per week and an increase of one or more bowel movements over baseline. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03638440
Study type Observational
Source Kyowa Kirin Pharmaceutical Development Ltd
Contact
Status Completed
Phase
Start date August 16, 2018
Completion date March 5, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02813369 - Naloxegol Health Outcome Post Authorisation Safety Study
Completed NCT01957046 - A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Phase 4
Completed NCT01401985 - A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) Phase 2
Completed NCT00984334 - Naloxone SR Capsules in Patients With Opioid Induced Constipation Phase 2
Completed NCT01207427 - Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain Phase 2
Completed NCT01459926 - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation Phase 2
Terminated NCT01117051 - Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation Phase 3
Completed NCT03060512 - To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Phase 4
Completed NCT01109511 - A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy Phase 4
Active, not recruiting NCT02813356 - Naloxegol US PMR CV Safety.
Completed NCT01812733 - Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives N/A
Completed NCT01623609 - Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol Phase 1
Completed NCT02813148 - Naloxegol Drug Utilization Post Authorisation Safety Study
Completed NCT01443403 - A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy Phase 2